DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for hemochromatosis type 5 — screening already-approved drugs against its 2-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleHemochromatosis type 5 maps to a 2-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for hemochromatosis type 5 is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
bestrophin 1 (BEST1) — BEST1 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet mc3drag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 8D1I · 1.82 Å · ligand 1,2-DIMYRISTOYL-RAC-GLYCERO-3-PHOSPHOCHOLINE (MC3). Experimental structure, not a prediction.
What the evidence adds up to
A 2005 systematic review for the American College of Physicians found no evidence that screening primary care patients for hereditary hemochromatosis does more good than harm. The prevalence in primary care ranged from 1 in 169 to 1 in 556 patients across three studies. Uncontrolled prospective studies of genetic homozygotes did not consistently show progression to overt disease. A serum ferritin below 1000 microg/L predicted absence of cirrhosis, but six studies showed reduced survival once cirrhosis was present. No blinded comparisons of screening tests against biopsy or quantitative phlebotomy were found, and no randomised controlled trials of phlebotomy existed. The review concluded that the available evidence does not demonstrate that benefits outweigh the risks and costs of screening.
A 2002 study of 110 consecutive subjects in a hospital referral clinic compared transferrin saturation and unsaturated iron binding capacity for detecting HFE genotypes that predispose to iron overload. Forty-four subjects carried C282Y/C282Y or C282Y/H63D mutations. The optimum threshold for transferrin saturation was 43%, giving a sensitivity of 0.88 and specificity of 0.95. For unsaturated iron binding capacity, the optimum threshold was 143 microg/dL, giving a sensitivity of 0.91 and specificity of 0.95. The authors concluded the two tests have equal reliability.
A 1976 article titled "The Inheritance of Hemochromatosis" is a journal article with no abstract or data available for summary.
A 2025 report on juvenile hemochromatosis described a patient with novel compound heterozygous mutations in the hemojuvelin gene. The authors suggested that long-term, strategic phlebotomy might offer a novel therapeutic strategy for severe juvenile hemochromatosis, challenging traditional treatment paradigms. This is a single-patient suggestion, not a tested protocol.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Annals of Internal Medicine · 2005 · 76 citations
Screening Primary Care Patients for Hereditary Hemochromatosis with Transferrin Saturation and Serum Ferritin Level: Systematic Review for the American College of Physicians
AbstractBACKGROUND: Therapeutic phlebotomy for hereditary hemochromatosis is relatively safe and presumably efficacious when offered before cirrhosis develops, so screening primary care patients is of substantial interest. PURPOSE: To conduct a systematic review of the evidence on 1) the prevalence of the disease in primary care, 2) the risk for morbid or fatal complications for untreated patients, 3) the diagnostic usefulness of transferrin saturation and serum ferritin level in identifying early disease, 4) the efficacy of early treatment, and 5) whether the benefits of screening outweigh the risks. DATA SOURCES: MEDLINE search from 1966 through April 2004, complemented by reference review of identified original studies and review articles published in English. STUDY SELECTION: PubMed Clinical Queries filters search of prognosis, diagnosis, etiology, or treatment were used depending on the question. Two authors reviewed all titles and abstracts. DATA EXTRACTION: Two investigators independently reviewed extracted data. DATA SYNTHESIS: The prevalence of hereditary hemochromatosis was 1 in 169 patients to 1 in 556 patients (n = 3 studies). Uncontrolled, prospective studies of genetic homozygous patients did not consistently identify a link to overt hereditary hemochromatosis. A serum ferritin level less than 1000 microg/L was predictive of absence of cirrhosis. Six studies demonstrated reduced survival in patients with cirrhosis. Diagnostic studies varied with respect to case definition. No blinded, independent comparisons of screening tests with the gold standard (biopsy or results of quantitative phlebotomy) or randomized, controlled trials of phlebotomy were identified. Cost-effectiveness analysis was limited by lack of prospective data on the natural history of the disease. LIMITATIONS: Varied case definition and lack of prospective cohort studies or randomized trials. CONCLUSIONS: The available evidence does not demonstrate that benefits outweigh the risks and costs of screening for hemochromatosis.
The American Journal of Gastroenterology · 2002 · 27 citations
Unsaturated iron binding capacity and transferrin saturation are equally reliable in detection of HFE hemochromatosis
AbstractOBJECTIVE: Unsaturated iron binding capacity (UIBC) has been proposed as an inexpensive alternative to transferrin saturation for detection of hereditary hemochromatosis. The aim of this study was to compare, in a hospital referral clinic, the reliability of transferrin saturation and UIBC for detection of subjects who have inherited HFE (HLA-asociated iron overload) genotypes predisposing to iron overload. METHODS: Serum transferrin saturation, UIBC, and ferritin were tested in 110 consecutive subjects. Optimum thresholds were determined from receiver operating characteristic curves. RESULTS: Of 110 subjects, 44 carried significant HFE mutations (C282Y/C282Y or C282Y/H63D). In genetically predisposed subjects with biochemical expression, the optimum threshold for transferrin saturation was 43%, giving a sensitivity of 0.88 and specificity 0.95. For UIBC, the optimum threshold was 143 microg/dL (25.6 micromol/L), giving a sensitivity of 0.91 and specificity of 0.95. In patients referred with a family history or clinical suspicion of hemochromatosis, transferrin saturation and UIBC were highly reliable predictors of genotype. In patients referred for investigation of abnormal liver enzymes without a known family history of hemochromatosis, a normal transferrin saturation or normal UIBC was highly reliable in excluding hemochromatosis. CONCLUSIONS: Transferrin saturation and UIBC have equal reliability in ability to predict hemochromatosis. UIBC should be considered as an alternative to transferrin saturation in detection of hemochromatosis.
American Journal of Clinical Pathology · 1976 · 1 citations
The Inheritance of Hemochromatosis
AbstractJournal Article The Inheritance of Hemochromatosis Get access J. P. Goossens J. P. Goossens Department of Internal Medicine Ziekenhuis Lievensberg Bergen op Zoom The Netherlands Search for other works by this author on: Oxford Academic Google Scholar American Journal of Clinical Pathology, Volume 66, Issue 1, 1 July 1976, Page 155, https://doi.org/10.1093/ajcp/66.1.155 Published: 01 July 1976
Journal of the American Geriatrics Society · 1977 · 1 citations
Idiopathic Hemochromatosis: Case Report of a Patient Presenting with Neurologic Symptoms
AbstractIdiopathic hemochromatosis is an iron-storage disease more common in men than in women. It is characterized clinically by diabetes mellitus, cirrhosis of the liver, pigmentation of the skin and cardiac failure. The diagnosis may be overlooked when the presenting symptoms do not follow the pattern. A case is reported which was diagnosed after an onset that featured neurologic symptoms.
World Journal of Clinical Cases · 2025 · 0 citations · open access
Reference diagnosis and treatment process of juvenile hemochromatosis patients
Abstract, published in a renowned medical journal, is an excellent example of meticulous clinical evaluation, comprehensive laboratory testing, advanced imaging, and genetic analysis. The authors identified novel compound heterozygous mutations in the hemojuvelin gene of a patient diagnosed with juvenile hemochromatosis. They suggested that long-term, strategic phlebotomy might offer a novel therapeutic strategy for severe juvenile hemochromatosis, challenging the traditional treatment paradigms.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
